Breaking barriers: Assessing the feasibility and acceptability of telemedicine-assisted buprenorphine induction for opioid use disorder in India.

ABSTRACT:

Background

Telemedicine-assisted buprenorphine (BNX) induction (TABI) has the potential to reduce the treatment gap for opioid use disorder.

Aim

This study investigated the acceptability and feasibility of TABI in India. This was a retrospective study from a specialized addiction treatment center in a teaching hospital.

Methods

TABI was introduced in November 2022; patients enrolled till May 2023 were included in the analysis. Feasibility was assessed by the proportion of patients who completed the TABI program, continued treatment for at least 3 months, and self-reported nonprescription opioid use during and after TABI. Acceptability was measured by patient satisfaction with TABI.

Results

Sixty patients were enrolled: Fifty-three patients (88.3%) were retained

SUBMITTER: Ghosh A 

PROVIDER: S-EPMC11633259 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature